Brief: MannKind, Sagard Healthcare Enter Royalty Purchase Agreement For Up To $200 Mln
02/01/2024 11:55
Jan 2 (Reuters) - MannKind Corp MNKD.O :
* MANNKIND AND SAGARD HEALTHCARE ENTER INTO ROYALTY PURCHASE
AGREEMENT FOR UP TO $200 MILLION
* MANNKIND CORP - PURCHASE PRICE OF $150 MILLION; ADDITIONAL
POTENTIAL MILESTONE PAYMENT OF UP TO $50 MILLION
* MANNKIND-IN DEAL TERMS,SAGARD HEALTHCARE TO GET ROYALTY
PAYMENTS
EQUAL TO 1% OF NET SALES OF TYVASO DPI THAT OCCUR BETWEEN OCT 1,
2023- DEC 31, 2042
Source text for Eikon: ID:nGNX4YQyf4
Further company coverage: MNKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on MannKind
See all newsBrief: MannKind Enters Data-Rich Development Period With Completion Of Randomization In Phase 1B Inflo-1 Study And Enrollment Of First Patient In Phase 2 Inflo-2 Trial For Nintedanib Dpi In Patients With Ipf
U.S. STOCKS ON THE MOVE-Dell, Gap, Costco
MannKind rises after FDA approves inhaled insulin for children
US FDA approves MannKind's inhaled insulin for children (updated)
US FDA approves MannKind's inhaled insulin for children